IMNN

0.53555.22%
JB

Joshua Blacher

CFO, Principal Financial Officer & Principal Accounting Officer

Mr. Joshua Blacher, M.B.A., C.P.A., also known as Josh, is Chief Financial Officer at Bullfrog AI Holdings, Inc. since December 12, 2024. He is CFO, Principal Financial Officer & Principal Accounting Officer of Imunon, Inc. from July 1, 2026. He was Chief Financial Officer at PineTree Therapeutics, Inc. since 2023. He served as Interim Chief Financial Officer at Axe Compute Inc. (formerly known as Predictive Oncology Inc.) since September 30, 2023 and served as its Chief Financial Officer until May 18, 2026. He has been the Chief Financial Officer of Excision BioTherapeutics, Inc. since 2024. Mr. Blacher served in senior capacities at Teva Pharmaceuticals, Deutsche Asset Management and Morgan Stanley. He has been Chief Financial Officer at South Rampart Pharma, LLC since August 2022. He served as the Chief Business Officer of InMed Pharmaceuticals Inc. since April 09, 2018 until August 2, 2019. He served as Consultant at LogicBio Therapeutics, Inc. since September 16, 2022 until September 23, 2022 and served as its Interim Chief Financial Officer, Principal Financial and Accounting Officer since September 23, 2022 until November 16, 2022. Mr. Blacher has served as a consultant with Danforth Advisors, Limited Liability Company since September 2022 and as Managing Partner of Columbus Circle Capital Limited Liability Company (“Columbus Circle Capital”) since August 2019. He was Chief Financial Officer at Therapix Biosciences Ltd. since April 2017 until April 2018. Mr. Blacher served as the Chief Financial Officer of Galmed Pharmaceuticals Ltd. since October 2014 until March, 2017. Mr. Blacher served as the Chief Financial Officer and Executive Vice President at Vestopia, Inc. Previously, he served as Director of Business Development at Teva Innovative Ventures. He served as Chief Financial Officer and Executive Vice President at SayHired, Inc. He served as Vice President of Business Development at Compugen Ltd. He helped build and manage Teva's portfolio of approximately 20 equity investments in biotech companies, spanning a wide range of development stage companies from pre-clinical through Phase III projects, as well as various therapeutic areas. Previously, Mr. Blacher also held positions in portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in mergers & acquisitions at Lehman Brothers. He served as Vice President at Deutsche Asset Management (Investment Management). He served as Research Analyst at Morgan Stanley, Research Division, Lehman Brothers (Investment Banking) and the Federal Reserve Bank of New York (Statistics). Mr. Blacher has an M.B.A. in Finance from Columbia Business School and B.A. in Economics from Yeshiva University.

Positions